Table 1.
Baseline demographics and clinical characteristics
| ACQUIRE [11] | ALLOWa [17] | ACCOMPANY [15] | ATTUNE [16] | AMPLE [19] | |||||
|---|---|---|---|---|---|---|---|---|---|
| Published inclusion criteria | ≥10 swollen joints, ≥12 tender joints, CRP ≥0.8 mg/dl | DAS28 (CRP) ≥3.2 and ≤5.1 | Global Assessment of Disease Activity VAS >20 | ≥4 years of treatment with i.v. abatacept in AIM or ATTAIN trial | ≤5 years disease duration, DAS28 (CRP) ≥3.2, history of anti-CCP or RF seropositivity, or elevated ESR or CRP | ||||
| Patient population | Active RA, MTX-IR | Active RA, MTX-IR | Active RA, IR to ≥1 DMARD (MTX-naïve or MTX-IR) | Active RA, MTX-IRb | Active RA, anti-TNF IRc | Active RA, MTX-IR, biologic-naïve | |||
| Treatment | s.c. abatacept + MTX | i.v. abatacept + MTX | s.c. abatacept + MTX | s.c. abatacept with/without MTX | s.c. abatacept | s.c. abatacept + MTX | s.c. adalimumab + MTX | ||
| Continuous | Withdrawal/ reintroduction | ||||||||
| n | 736 | 721 | 40 | 80 | 100 | 71 | 52 | 318 | 328 |
| Age, years | 49.9 (13.2) | 50.1 (12.6) | 48.9 (14.2) | 49.1 (12.8) | 54.0 (10.9) | 52.8 (13.8) | 56.5 (10.2) | 51.4 (12.6) | 51.0 (12.8) |
| Weight, kg | 72.0 (18.0) | 71.8 (17.6) | 67.9 (15.8) | 68.9 (14.7) | 83.1 (20.6) | NR | NR | 80.8 (20.3) | 80.1 (20.7) |
| Gender, % female | 84.4 | 80.4 | 85.0 | 83.8 | 75.0 | 83.1 | 80.8 | 81.4 | 82.3 |
| Ethnicity, % Caucasian | 74.7 | 74.5 | 95.0 | 93.8 | 76.0 | 98.6 | 90.4 | 80.8 | 78.0 |
| Disease duration, years | 7.6 (8.1) | 7.7 (7.8) | 7.4 (7.7) | 6.2 (5.8) | 10.1 (11.1) | NR | NR | 1.9 (1.4) | 1.7 (1.4) |
| DAS28 (CRP) | 6.2 (0.9) | 6.2 (0.8) | 4.8 (0.8) | 4.8 (0.8) | 5.4 (1.4) | 3.3 (1.3) | 3.6 (1.2) | 5.5 (1.1) | 5.5 (1.1) |
| HAQ-DI score | 1.7 (0.7) | 1.7 (0.7) | 1.4 (0.7) | 1.3 (0.7) | 1.4 (0.7) | 0.9 (0.7) | 1.0 (0.7) | 1.5 (0.7) | 1.5 (0.7) |
| Tender joints | 30.1 (14.1) | 29.1 (13.3) | 13.6 (7.7) | 14.6 (9.2) | 24.1 (16.2) | 8.8 (12.4) | 9.1 (12.8) | 25.4 (15.3) | 26.3 (15.8) |
| Swollen joints | 20.4 (9.6) | 19.4 (8.6) | 10.5 (5.4) | 10.6 (5.4) | 17.2 (12.1) | 4.3 (5.9) | 5.4 (6.4) | 15.8 (9.8) | 15.9 (10.0) |
| RF positive, % | 84.8 | 85.9 | 85.0 | 86.1 | 67.0 | NR | NR | 75.5 | 77.4 |
Data are mean (s.d.), unless otherwise stated. aData are presented for patients treated in period II; baseline is the start of period I. NR: not reported; VAS: visual analogue scale. bPatient recruited from the AIM study (Abatacept in Inadequate Responders to Methotrexate). cPatients recruited from the ATTAIN study (Abatacept Trial in Treatment of Anti-TNF Inadequate responders).